Arrhythmias & electrophysiology

The Interaction Between Atrial Fibrillation and Mitral Regurgitation: Insights from the CABANA Randomized Clinical Trial

Eur J Heart FailPublished Secondary analysis of the CABANA randomised trial

Authors' conclusion

Catheter ablation was superior to pharmacological therapy in rhythm control and may reduce MR severity over time.

Study context

Population
CABANA patients with atrial fibrillation (AF) and available baseline echocardiography; 722 (52%) had mitral regurgitation (MR) (582 mild, 140 ≥moderate)65% of CABANA cohort
Participants
1,423 patients
Comparison
Catheter ablation vs pharmacological therapy in AF with or without baseline MR
Primary endpoint
All-cause mortality and CV hospitalization (composite)
Methodological detailssub-analysis
  • Sub-analysis

Primary result

As reported in the abstract

All-cause mortality and CV hospitalization, by MR
MR presence or absence did not interact with randomization in its neutral effect on all-cause mortality and CV hospitalization
p for interaction = 0.115

Secondary outcomes

OutcomeOR (95% CI)P value
AF recurrence0.56 (0.50–0.62)P < 0.001
AF recurrence, baseline MRvs no MR1.46 (1.40–1.74)P < 0.001

Functional status, by MR

Benefit of ablation on functional status greater with MR than without
P for interaction < 0.001

MR severity change (follow-up echocardiography, n = 248)

Greater reduction in MR severity with ablation vs drug therapy
P for interaction = 0.040

Original publication

The Interaction Between Atrial Fibrillation and Mitral Regurgitation: Insights from the CABANA Randomized Clinical Trial. Eur J Heart Fail. Published 21 April 2025. doi:10.1002/ejhf.3668

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.